AAB-001

bapineuzumab · Janssen Alzheimer Immunotherapy Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AAB-001, covering 2012-03-14 to 2012-03-14. Get the full timeline:

Most recent: Clinical Trial Update: AAB-001 in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]